The clinical course of spontaneous dural sinus thrombosis in children varies from indolent to fulminant. Although many different etiologies for the development of dural sinus thrombosis have been described, a full recovery can be anticipated in most children following rehydration and the administration of systemic antibiotics. Steroids, systemic anticoagulation and intrasinus thrombolysis may be beneficial in selected patients, although the efficacy of these therapies has not been established prospectively in children. We reviewed 12 pediatric patients with spontaneous dural sinus thrombosis (1978-1998) to determine the etiology, clinical course and best treatment options. In the absence of a hypercoagulable state, pediatric patients generally recover well with rehydration and antibiotics and do not require anticoagulation.

Keywords:
Child, Dura, Hypercoagulable state, Thrombosis, Venous sinus
1.
Di Rocco C, Iannelli A, Leone G, Moschini M, Valori VM: Heparin-urokinase treatment in aseptic dural sinus thrombosis. Arch Neurol 1981;38:431–435.
2.
Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Habrel RL, Pfister HW, Schmidek P: Heparin treatment in sinus venous thrombosis. Lancet 1991;338:597–600.
3.
Horowitz M, Purdy P, Unwin H, Carstens G III, Greenlee R, Hise J, Kopitnik T, Batjer H, Rollins N, Samson D: Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995;38:58–67.
4.
Kim SY, Suh JH: Direct endovascular thrombolytic therapy for dural sinus thrombosis: Infusion of alteplase. AJNR 1997;18:639–645.
5.
Niwa J, Ohyama H, Matumura S, Maeda Y, Shimizu T: Treatment of acute sagittal sinus thrombosis by t-PA infusion via venography – Direct thrombolytic therapy in the acute phase. Surg Neurol 1998;49:425–429.
6.
Roach ES, Riela AR: Sinovenous occlusion; in Roach ES, Riela AR: Pediatric Cerebrovascular Disorders. New York, Futura Publishing Company, 1995, pp 239–256.
7.
Medlock MD, Olivero WC, Hanigan WC, Wright RM, Winek SJ: Children with cerebral venous thrombosis diagnosed with magnetic resonance imaging and magnetic resonance angiography. Neurosurgery 1992;31:870–876.
8.
Reddingius RE, Patte C, Couanet D, Kalifa C, Lemerle J: Dural sinus thrombosis in children with cancer. Med Pediatr Oncol 1997;29:296–302.
9.
Wechsler B, Vidailhet M, Piette JC, Bousser MG, Isola BD, Bletry O, Godeau P: Cerebral venous thrombosis in Behcet’s disease: Clinical study and long term follow-up of 25 cases. Neurology 1992;42:614–618.
10.
Barnwell SL, Higashida RT, Halbach VH, Dowd CF, Hieshima GB: Direct endovascular thrombolytic therapy for dural sinus thrombosis. Neurosurgery 1991;28:135–142.
11.
Gebara BM, Goetting MG, Wang AM: Dural sinus thrombosis complicating subclavian vein catheterization: Treatment with local thrombolysis. Pediatrics 1995;95:138–140.
12.
Gerszten PC, Welch WC, Spearman MP, Jungreis CA, Redner RL: Isolated deep cerebral venous thrombosis treated by direct endovascular thrombolysis. Surg Neurol 1997;48:261–266.
13.
Griesemer DA, Theodorou AA, Berg RA, Spera TD: Local fibrinolysis in cerebral thrombosis. Pediatr Neurol 1994;10:78–80.
14.
Gurley MB, King TS, Tsai FY: Sigmoid sinus thrombosis associated with internal jugular vein occlusion: Direct thrombolytic treatment. J Endovasc Surg 1996;3:306–314.
15.
Higashida RT, Helmer E, Halbach VV, Hieshima GB: Direct thrombolytic therapy for superior sagittal sinus thrombosis. AJNR 1989;10 (suppl 5):S4–S6.
16.
Satake R, Arakawa S, Hashimoto M, Minamide H, Takamori M: Successful direct thrombolysis in a patient with extensive dural sinus thrombosis induced by danazol. Rinsho Shinkei Gaku 1997;37:309–313.
17.
Scott JA, Pascuzzi RM, Hall PV, Becker GJ: Treatment of dural sinus thrombosis with local urokinase infusion. J Neurosurg 1988;68:284–287.
18.
Smith TP, Higashida RT, Barnwell SL, Halbach VV, Dowd CF, Fraser KW, Teitelbaum GP, Hieshima GB: Treatment of dural sinus thrombosis by urokinase infusion. AJNR 1994;15:801–807.
19.
Takami T, Suzuki T, Tokuno H, Egashira M, Tsuyuguchi N, Komiyama M, Hakuba A: A case report of dural sinus thrombosis: Direct thrombolytic therapy using endovascular surgery. No Shinkei Geka 1995;23:321–325.
20.
Tsai FY, Higashida RT, Matovich V, Alfieri K: Acute thrombosis of the intracranial dural sinus: Direct thrombolytic treatment. AJNR 1992;13:1137–1141.
21.
Van Dyke DC, Eldadah MK, Bale JF, Kramer M, Alexander R, Smith WL, Olivero W: Mycoplasma pneumonia-induced cerebral venous thrombosis treated with urokinase. Clin Pediatr 1992;31:501–504.
22.
Byers RK, Hass GM: Thrombosis of the dural venous sinuses in infancy and childhood. Am J Dis Child 1933;45:1161–1183.
23.
Baram TZ, Butler IJ, Nelson MD Jr, McArdle CB: Transverse sinus thrombosis in newborns: Clinical and magnetic resonance imaging findings. Ann Neurol 1988;24:792–794.
24.
Barron TF, Gusnard DA, Zimmerman RA, Clancy RR: Cerebral venous thrombosis in neonates and children. Pediatr Neurol 1990;18:112–116.
25.
Brown MT, Freidman HS, Oakes WJ, Boyko OB, Schold SC Jr: Sagittal sinus thrombosis and leptomeningeal medulloblastoma. Neurology 1991;41:455–456.
26.
Lee BC, Park TS, Kaufman BA: MR angiography in pediatric neurological disorders. Pediatr Radiol 1995;25:409–419.
27.
Rich C, Gill JC, Wernick S, Konkol RJ: An unusual cause of cerebral venous thrombosis in a four-year-old child. Stroke 1993;24:603–605.
28.
Rivkin MJ, Anderson ML, Kaye EM: Neonatal idiopathic cerebral venous thrombosis: An unrecognized cause of transient seizures and lethargy. Ann Neurol 1992;32:51–56.
29.
Wong VK, Lemesurier J, Franceschini R, Heikali M, Hanson R: Cerebral venous thrombosis as a cause of neonatal seizures. Pediatr Neurol 1987;3:235–237.
30.
Tsai FY, Wang A-M, Matovich VB, Lavin M, Berberian B, Simonson TA, Yuh WTC: MR staging of acute dural sinus thrombosis: Correlation with venous pressure measurements and implications for treatment and prognosis. AJNR 1995;16:1021–1029.
31.
Singh B: The management of lateral sinus thrombosis. J Laryngol Otol 1993;107:803–808.
32.
Goldenberg RA: Lateral sinus thrombosis. Arch Otolaryngol 1985;111:56–58.
33.
Kaplan RE, Springate JE, Feld LG, Cohen ME: Pseudotumor cerebri associated with cerebral venous sinus thrombosis, internal jugular vein thrombosis, and systemic lupus erythematosus. J Pediatr 1985;107:266–268.
34.
Stansfield FR: Puerperal cerebral venous thrombosis treated with heparin. Br Med J 1942;1:436–438.
35.
Sindou M, Mercier P, Bokor J, Brunon J: Bilateral thrombosis of the transverse sinuses: Microsurgical revascularization with venous bypass. Surg Neurol 1980;13:215–220.
36.
Kourtopoulous H, Christie M, Rath B: Open thrombectomy combined with thrombolysis in massive intracranial sinus thrombosis. Acta Neurochir (Wien) 1994;128:171–173.
37.
Persson L, Lilja A: Extensive dural sinus thrombosis treated by surgical removal and local streptokinase infusion. Neurosurgery 1990;26:117–121.
38.
Persson L, Bostrom S, Bynke O, Bjorn A, Lilja A, Noren G, Thomas KA: Neurosurgical treatment of severe sinus thrombosis: Experience with 10 cases. Hygiea 1991;100:245.
39.
Ekseth K, Bostrom S, Vegfors M: Reversibility of severe sagittal sinus thrombosis with open surgical thrombectomy combined with local infusion of tissue plasminogen activator: Technical case report. Neurosurgery 1998;43:960–965.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.